CD3×CD19 bispecific antibodies can mediate effective killing of CLL cells regardless of IGVH and TP53 mutational status, irrespective of sensitivity to ibrutinib. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.